Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Engaging patients to improve quality of care: a systematic review.

Bombard Y, Baker GR, Orlando E, Fancott C, Bhatia P, Casalino S, Onate K, Denis JL, Pomey MP.

Implement Sci. 2018 Jul 26;13(1):98. doi: 10.1186/s13012-018-0784-z. Review.

2.

Genome-wide sequencing in acutely ill infants: genomic medicine's critical application?

Friedman JM, Bombard Y, Cornel MC, Fernandez CV, Junker AK, Plon SE, Stark Z, Knoppers BM; Paediatric Task Team of the Global Alliance for Genomics and Health Regulatory and Ethics Work Stream.

Genet Med. 2018 Jun 12. doi: 10.1038/s41436-018-0055-z. [Epub ahead of print]

PMID:
29895853
3.

The Genetic Non-Discrimination Act: critical for promoting health and science in Canada.

Bombard Y, Heim-Myers B.

CMAJ. 2018 May 14;190(19):E579-E580. doi: 10.1503/cmaj.180298. No abstract available.

PMID:
29759963
4.

The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results.

Bombard Y, Clausen M, Mighton C, Carlsson L, Casalino S, Glogowski E, Schrader K, Evans M, Scheer A, Baxter N, Hamilton JG, Lerner-Ellis J, Offit K, Robson M, Laupacis A.

Eur J Hum Genet. 2018 Jul;26(7):984-995. doi: 10.1038/s41431-018-0144-0. Epub 2018 Apr 27.

PMID:
29703952
5.

Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial.

Shickh S, Clausen M, Mighton C, Casalino S, Joshi E, Glogowski E, Schrader KA, Scheer A, Elser C, Panchal S, Eisen A, Graham T, Aronson M, Semotiuk KM, Winter-Paquette L, Evans M, Lerner-Ellis J, Carroll JC, Hamilton JG, Offit K, Robson M, Thorpe KE, Laupacis A, Bombard Y.

BMJ Open. 2018 Apr 26;8(4):e021876. doi: 10.1136/bmjopen-2018-021876.

6.

The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants.

Reuter MS, Walker S, Thiruvahindrapuram B, Whitney J, Cohn I, Sondheimer N, Yuen RKC, Trost B, Paton TA, Pereira SL, Herbrick JA, Wintle RF, Merico D, Howe J, MacDonald JR, Lu C, Nalpathamkalam T, Sung WWL, Wang Z, Patel RV, Pellecchia G, Wei J, Strug LJ, Bell S, Kellam B, Mahtani MM, Bassett AS, Bombard Y, Weksberg R, Shuman C, Cohn RD, Stavropoulos DJ, Bowdin S, Hildebrandt MR, Wei W, Romm A, Pasceri P, Ellis J, Ray P, Meyn MS, Monfared N, Hosseini SM, Joseph-George AM, Keeley FW, Cook RA, Fiume M, Lee HC, Marshall CR, Davies J, Hazell A, Buchanan JA, Szego MJ, Scherer SW.

CMAJ. 2018 Feb 5;190(5):E126-E136. doi: 10.1503/cmaj.171151.

7.

What's Involved with Wanting to Be Involved? Comparing Expectations for Public Engagement in Health Policy across Research and Care Contexts.

Barg CJ, Miller FA, Hayeems RZ, Bombard Y, Cressman C, Painter-Main M.

Healthc Policy. 2017 Nov;13(2):40-56.

PMID:
29274226
8.

Human Germline Genome Editing.

Ormond KE, Mortlock DP, Scholes DT, Bombard Y, Brody LC, Faucett WA, Garrison NA, Hercher L, Isasi R, Middleton A, Musunuru K, Shriner D, Virani A, Young CE.

Am J Hum Genet. 2017 Aug 3;101(2):167-176. doi: 10.1016/j.ajhg.2017.06.012. Review.

9.

Q-SEA - a tool for quality assessment of ethics analyses conducted as part of health technology assessments.

Scott AM, Hofmann B, Gutiérrez-Ibarluzea I, Bakke Lysdahl K, Sandman L, Bombard Y.

GMS Health Technol Assess. 2017 Mar 15;13:Doc02. doi: 10.3205/hta000128. eCollection 2017.

10.

Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis.

Hayeems RZ, Miller FA, Barg CJ, Bombard Y, Carroll JC, Tam K, Kerr E, Chakraborty P, Potter BK, Patton S, Bytautas JP, Taylor L, Davies C, Milburn J, Price A, Gonska T, Keenan K, Ratjen F, Guttmann A.

J Pediatr. 2017 May;184:165-171.e1. doi: 10.1016/j.jpeds.2017.01.049. Epub 2017 Mar 6.

PMID:
28279431
11.

Universal tumor screening for Lynch syndrome: health-care providers' perspectives.

Bombard Y, Rozmovits L, Sorvari A, Daly C, Carroll JC, Kennedy E, Rabeneck L, Baxter NN.

Genet Med. 2017 May;19(5):568-574. doi: 10.1038/gim.2016.150. Epub 2016 Oct 6.

PMID:
27711070
12.

A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis.

Bombard Y, Miller FA, Barg CJ, Patton SJ, Carroll JC, Chakraborty P, Potter BK, Tam K, Taylor L, Kerr E, Davies C, Milburn J, Ratjen F, Guttmann A, Hayeems RZ.

Genet Med. 2017 Apr;19(4):403-411. doi: 10.1038/gim.2016.125. Epub 2016 Sep 8.

13.

Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis.

Hayeems RZ, Miller FA, Barg CJ, Bombard Y, Kerr E, Tam K, Carroll JC, Potter BK, Chakraborty P, Davies C, Milburn J, Patton S, Bytautas JP, Taylor L, Price A, Gonska T, Keenan K, Ratjen F, Guttmann A.

Pediatrics. 2016 Sep;138(3). pii: e20161052. doi: 10.1542/peds.2016-1052. Epub 2016 Aug 2.

14.

How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.

Marshall DA, Deal K, Bombard Y, Leighl N, MacDonald KV, Trudeau M.

BMJ Open. 2016 Jun 2;6(6):e010981. doi: 10.1136/bmjopen-2015-010981. Erratum in: BMJ Open. 2016 Jun 23;6(6):e010981corr1.

15.

Using Newborn Screening Bloodspots for Research: Public Preferences for Policy Options.

Hayeems RZ, Miller FA, Barg CJ, Bombard Y, Cressman C, Painter-Main M, Wilson B, Little J, Allanson J, Avard D, Giguere Y, Chakraborty P, Carroll JC.

Pediatrics. 2016 Jun;137(6). pii: e20154143. doi: 10.1542/peds.2015-4143. Epub 2016 May 17.

16.

The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.

MacDonald KV, Bombard Y, Deal K, Trudeau M, Leighl N, Marshall DA.

Eur J Cancer. 2016 Jul;61:85-93. doi: 10.1016/j.ejca.2016.03.077. Epub 2016 May 4.

PMID:
27155447
17.

Translating personalized genomic medicine into clinical practice: evidence, values, and health policy.

Bombard Y.

Genome. 2015 Dec;58(12):491-7. doi: 10.1139/gen-2015-0145. Epub 2015 Nov 18. No abstract available.

PMID:
26577841
18.

Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.

Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, Chitty LS, Fellmann F, Forzano F, Hall A, Henneman L, Howard HC, Lucassen A, Ormond K, Peterlin B, Radojkovic D, Rogowski W, Soller M, Tibben A, Tranebjærg L, van El CG, Cornel MC.

Eur J Hum Genet. 2015 Nov;23(11):1592. doi: 10.1038/ejhg.2015.109. No abstract available.

19.

Public Perceptions of the Benefits and Risks of Newborn Screening.

Miller FA, Hayeems RZ, Bombard Y, Cressman C, Barg CJ, Carroll JC, Wilson BJ, Little J, Allanson J, Chakraborty P, Giguère Y, Regier DA.

Pediatrics. 2015 Aug;136(2):e413-23. doi: 10.1542/peds.2015-0518. Epub 2015 Jul 13.

20.

Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents.

Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA, Levy HP, Ormond KE, Saal HM, Spinner NB, Wilfond BS, McInerney JD.

Am J Hum Genet. 2015 Jul 2;97(1):6-21. doi: 10.1016/j.ajhg.2015.05.022. Review. Erratum in: Am J Hum Genet. 2015 Sep 3;97(3):501.

21.

Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Summary and recommendations.

Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, Chitty LS, Fellmann F, Forzano F, Hall A, Henneman L, Howard HC, Lucassen A, Ormond K, Peterlin B, Radojkovic D, Rogowski W, Soller M, Tibben A, Tranebjærg L, van El CG, Cornel MC.

Eur J Hum Genet. 2015 Apr 1. doi: 10.1038/ejhg.2015.56. [Epub ahead of print] No abstract available.

22.

Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.

Dondorp W, de Wert G, Bombard Y, Bianchi DW, Bergmann C, Borry P, Chitty LS, Fellmann F, Forzano F, Hall A, Henneman L, Howard HC, Lucassen A, Ormond K, Peterlin B, Radojkovic D, Rogowski W, Soller M, Tibben A, Tranebjærg L, van El CG, Cornel MC; European Society of Human Genetics; American Society of Human Genetics.

Eur J Hum Genet. 2015 Nov;23(11):1438-50. doi: 10.1038/ejhg.2015.57. Epub 2015 Mar 18. Erratum in: Eur J Hum Genet. 2015 Nov;23(11):1592.

23.

The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.

Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA.

Oncologist. 2015 Apr;20(4):351-6. doi: 10.1634/theoncologist.2014-0268. Epub 2015 Mar 6.

24.

The Influence Of Gene Expression Profiling (GEP) On Decisional Conflict In Chemotherapy Treatment Decision-Making For Early-Stage Breast Cancer (BRCA).

Marshall D, MacDonald K, Deal K, Trudeau M, Leighl N, Bombard Y.

Value Health. 2014 Nov;17(7):A569. doi: 10.1016/j.jval.2014.08.1899. Epub 2014 Oct 26. No abstract available.

25.

Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.

Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA.

Curr Oncol. 2014 Jun;21(3):e426-33. doi: 10.3747/co.21.1782.

26.

Patients' perceptions of gene expression profiling in breast cancer treatment decisions.

Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA.

Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524.

27.

Public views on participating in newborn screening using genome sequencing.

Bombard Y, Miller FA, Hayeems RZ, Barg C, Cressman C, Carroll JC, Wilson BJ, Little J, Avard D, Painter-Main M, Allanson J, Giguere Y, Chakraborty P.

Eur J Hum Genet. 2014 Nov;22(11):1248-54. doi: 10.1038/ejhg.2014.22. Epub 2014 Feb 19.

28.

Translating genomics in cancer care.

Bombard Y, Bach PB, Offit K.

J Natl Compr Canc Netw. 2013 Nov;11(11):1343-53. Review.

PMID:
24225968
29.

Revealing the incidentalome when targeting the tumor genome.

Bombard Y, Robson M, Offit K.

JAMA. 2013 Aug 28;310(8):795-6. doi: 10.1001/jama.2013.276573. No abstract available.

30.

Assessing the impacts of citizen deliberations on the health technology process.

Abelson J, Bombard Y, Gauvin FP, Simeonov D, Boesveld S.

Int J Technol Assess Health Care. 2013 Jul;29(3):282-9. doi: 10.1017/S0266462313000299. Erratum in: Int J Technol Assess Health Care. 2013 Oct;29(4):466.

PMID:
23863188
31.

Expectations and values about expanded newborn screening: a public engagement study.

Hayeems RZ, Miller FA, Bombard Y, Avard D, Carroll J, Wilson B, Little J, Chakraborty P, Bytautas J, Giguere Y, Allanson J, Axler R.

Health Expect. 2015 Jun;18(3):419-29. doi: 10.1111/hex.12047. Epub 2013 Feb 1.

32.

Citizens' perspectives on personalized medicine: a qualitative public deliberation study.

Bombard Y, Abelson J, Simeonov D, Gauvin FP.

Eur J Hum Genet. 2013 Nov;21(11):1197-201. doi: 10.1038/ejhg.2012.300. Epub 2013 Jan 23.

33.

Knowledge of the Genetic Information Nondiscrimination act among individuals affected by Huntington disease.

Dorsey ER, Darwin KC, Nichols PE, Kwok JH, Bennet C, Rosenthal LS, Bombard Y, Shoulson I, Oster E.

Clin Genet. 2013 Sep;84(3):251-7. doi: 10.1111/cge.12065. Epub 2012 Dec 20.

PMID:
23167775
34.

Risks to relatives in genomic research: a duty to warn?

Bombard Y, Offit K, Robson ME.

Am J Bioeth. 2012;12(10):12-4. doi: 10.1080/15265161.2012.699157. No abstract available.

PMID:
22974020
35.

Genetic discrimination: international perspectives.

Otlowski M, Taylor S, Bombard Y.

Annu Rev Genomics Hum Genet. 2012;13:433-54. doi: 10.1146/annurev-genom-090711-163800. Epub 2012 May 15. Review.

PMID:
22607273
36.

Reply to Ross' commentary: Reproductive benefit through newborn screening: preferences, policy and ethics.

Bombard Y, Miller FA.

Eur J Hum Genet. 2012 May;20(5):486-7. doi: 10.1038/ejhg.2012.25. Epub 2012 Feb 29. No abstract available.

37.

Citizens' values regarding research with stored samples from newborn screening in Canada.

Bombard Y, Miller FA, Hayeems RZ, Carroll JC, Avard D, Wilson BJ, Little J, Bytautas JP, Allanson J, Axler R, Giguere Y, Chakraborty P.

Pediatrics. 2012 Feb;129(2):239-47. doi: 10.1542/peds.2011-2572. Epub 2012 Jan 16.

PMID:
22250019
38.

Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease.

Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR; Canadian Respond-HD Collaborative Research Group.

Am J Med Genet B Neuropsychiatr Genet. 2012 Mar;159B(2):217-26. doi: 10.1002/ajmg.b.32016. Epub 2012 Jan 9.

PMID:
22231990
39.

Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders.

Bombard Y, Miller FA, Hayeems RZ, Wilson BJ, Carroll JC, Paynter M, Little J, Allanson J, Bytautas JP, Chakraborty P.

Eur J Hum Genet. 2012 May;20(5):498-504. doi: 10.1038/ejhg.2011.188. Epub 2011 Nov 9.

40.

An equity framework for health technology assessments.

Culyer AJ, Bombard Y.

Med Decis Making. 2012 May-Jun;32(3):428-41. doi: 10.1177/0272989X11426484. Epub 2011 Nov 7.

PMID:
22065143
41.

When they hear what we say: ethical challenges in presenting research findings to the Huntington disease community.

Bombard Y, Cox SM, Semaka A.

J Empir Res Hum Res Ethics. 2011 Sep;6(3):47-54. doi: 10.1525/jer.2011.6.3.47.

PMID:
21931237
42.

Eliciting ethical and social values in health technology assessment: A participatory approach.

Bombard Y, Abelson J, Simeonov D, Gauvin FP.

Soc Sci Med. 2011 Jul;73(1):135-44. doi: 10.1016/j.socscimed.2011.04.017. Epub 2011 May 23.

PMID:
21664018
43.

Adoption and the communication of genetic risk: experiences in Huntington disease.

Bombard Y, Semaka A, Hayden MR.

Clin Genet. 2012 Jan;81(1):64-9. doi: 10.1111/j.1399-0004.2010.01614.x. Epub 2011 Jan 9.

PMID:
21204796
44.

Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease.

Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Paulsen JS, Bottorff JL, Hayden MR; Canadian Respond-HD Collaborative Research Group.

Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):19-27. doi: 10.1002/ajmg.b.31130. Epub 2010 Nov 10.

45.

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study.

Williams JK, Erwin C, Juhl AR, Mengeling M, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1150-9. doi: 10.1002/ajmg.b.31080.

46.

Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study.

Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1081-93. doi: 10.1002/ajmg.b.31079.

47.

Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening.

Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM.

Eur J Hum Genet. 2010 Jul;18(7):751-60. doi: 10.1038/ejhg.2010.13. Epub 2010 Mar 3. Review.

48.

Clinical obligations and public health programmes: healthcare provider reasoning about managing the incidental results of newborn screening.

Miller FA, Hayeems RZ, Bombard Y, Little J, Carroll JC, Wilson B, Allanson J, Paynter M, Bytautas JP, Christensen R, Chakraborty P.

J Med Ethics. 2009 Oct;35(10):626-34. doi: 10.1136/jme.2009.030346.

PMID:
19793944
49.

The expansion of newborn screening: is reproductive benefit an appropriate pursuit?

Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM, Cornel MC, Borry P.

Nat Rev Genet. 2009 Oct;10(10):666-7. doi: 10.1038/nrg2666. No abstract available.

PMID:
19763150
50.

Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey.

Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, Paulsen JS, Bottorff JL, Hayden MR; Canadian Respond-HD Collaborative Research Group.

BMJ. 2009 Jun 9;338:b2175. doi: 10.1136/bmj.b2175.

Supplemental Content

Loading ...
Support Center